Aortic wall

The **aortic wall** is not a discrete molecular or protein target, but rather the complex multi-layered structure forming the wall of the aorta, the body’s largest artery. It is composed of three major layers: the tunica intima (inner endothelium and subendothelial connective tissue), tunica media (thick middle layer with smooth muscle cells, elastic fibers, and collagen), and tunica adventitia (outer layer with connective tissue, collagen, elastic fibers, fibroblasts, and vasa vasorum)[5][2]. The extracellular matrix (ECM) proteins in the aortic wall, including elastin, collagens (type I and III predominating), proteoglycans, and glycoproteins, provide the mechanical strength, elasticity, and resilience needed for the aorta to withstand and absorb pulse pressure from cardiac output[2][5][4]. Functionally, the aortic wall serves to maintain vascular integrity, modulate biomechanical stress, and play a central role in vascular pathologies such as aneurysm formation and dissection. Pathological remodeling is mediated by increased activity of proteases such as matrix metalloproteinases and changes in ECM composition, contributing to diseases like aneurysms and dissections[4][2][6]. The aortic wall itself is not a drug target in the sense of a specific receptor, enzyme, or molecular complex, but rather a tissue structure whose integrity is influenced by cellular and molecular processes. **Note:** - "Aortic wall" is not a molecular, enzymatic, receptor, or transporter target. It refers to a tissue structure, so classifying it as a "therapeutic target" in the context of drug development for molecular targets is incorrect. This is a common error in biomedical data modeling. - Drugs do not interact directly with the physical "aortic wall," but may modulate molecular pathways (e.g., MMP inhibitors) implicated in aortic wall pathology. - Relevant biomarkers include proteins central to its remodeling or degradation, e.g., matrix metalloproteinases[4]. - Safety concerns relate to risks of rupture or degeneration in disease states, not to drugging the wall per se. **Summary:** The aortic wall is a vascular tissue, not a canonical molecular target. Listing it as a "target" is incorrect for purposes of molecular drug development. While it plays critical roles in cardiovascular pathology, interventions target underlying molecular processes, not the wall as a direct receptor or protein entity[2][4][5][6].